HCW Biologics Inc. (HCWB) stock
HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
HCW Biologics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
HCW Biologics's operating cash flow for the twelve months ending Jun 30, 2026 was -$12.14M. For fiscal 2025 it was -$13.39M. The highest annual figure on record is -$10.39M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.39M | – |
| FY2024 | Dec 31, 2024 | -$14.23M | – |
| FY2023 | Dec 31, 2023 | -$22.51M | – |
| FY2022 | Dec 31, 2022 | -$10.39M | – |
| FY2021 | Dec 31, 2021 | -$10.98M | – |
| FY2020 | Dec 31, 2020 | -$10.43M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.36M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.51M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.83M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.93M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.86M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.59M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.64M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.31M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.59M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.38M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.12M | – |
| Q2 FY2021 | Jun 30, 2021 | -$990.44K | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.49M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.54M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.75M | – |
See a number that looks wrong?